

The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島成立之有限公司)

(Stock code 股份代號: 3933)

NOTIFICATION LETTER 通知信函

30 September 2025

Dear Shareholder,

The United Laboratories International Holdings Limited (the "Company") Notice of Publication of 2025 Interim Report ("Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.tul.com.hk and the HKExnews' website at www.tul.com.hk and the

Arrangement of Electronic Dissemination of Corporate Communications (Note 1)

Pursuant to Rule 2.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under the expansion of paperless listing regime and electronic dissemination of Corporate Communications that came into effect on 31 December 2023, the Company has adopted electronic dissemination of Corporate Communications. Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the Company's website and the HKExnews' website, in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the latest Corporate Communications, the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Hong Kong Branch Share Registrar. If your email address provided is not functional, until such time that the functional email address is provided to the Hong Kong Branch Share Registrar, you may (i) be unable to receive any notifications regarding the publication of Corporate Communications; (ii) need to proactively check the Company's website and the HKExnews' website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications.

If you want to receive a printed version of future Corporate Communications of the Company, please complete the Reply Form and send it to the Hong Kong Branch Share Registrar by using the mailing label at the bottom of the Reply Form (need not affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). You may also send email with a scanned copy of the completed Reply Form to tul3933.ecom@computershare.com.hk. Please note that such request shall be valid up to the time when the Company publishes its next annual report in the following year.

Should you have any queries relating to any of the above matters, please call the Hong Kong Branch Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays or send an email to tul3933.ecom@computershare.com.hk.

By Order of the Board of
The United Laboratories International Holdings Limited
Leung Wing Hon

Company Secretary

- (1) Corporate Communications include but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
 - (2) Actionable Corporate Communication is any corporate communication that seeks instructions from the Company's securities holders on how they wish to exercise their rights or make an election as the Company's securities holder.

各位股東:

Notes:

聯邦制藥國際控股有限公司(「本公司」) 2025年中期報告(「本次公司通訊文件」)之發佈通知

本公司的本文公司通訊文件中、英文版本已上載於本公司網站(www.tul.com.hk)及香港交易所披露易網站(www.hkexnews.hk),歡迎瀏覽。或按安排附上本次公司通訊文件之印刷本(如適用)。如 閣下若因任何理由以致在收取或接收本次公司通訊文件出現困難或希望收取本次公司通訊文件的印刷版本,我們會在收到 閣下的要求後,盡快向 閣下提供所要求的本次公司通訊文件的印刷版本,費用全免; 閣下可以書面方式通知香港中央證券登記有限公司(「香港股份過戶登記分處」),地址為香港灣仔皇后大道東 183 號合和中心 17M 樓,或電郵至 tul3933.ecom@computershare.com.hk。

以電子方式發佈公司通訊文件^(解註 1)之安排

根據自2023年12月31日起生效的擴大無紙化制度及以電子方式發佈公司通訊文件規定下香港聯合交易所有限公司證券上市規則第2.07條,本公司已採用以電子方式發佈公司通訊 文件之安排。請注意,所有日後公司通訊文件的中、英文版本將上載於本公司網站和香港交易所披露易網站,以代替印刷本。

徵集電子聯絡資料

為確保及時收到最新的公司通訊文件,本公司建議閣下透過掃描本函隨附之回條(「回條」)上列印的閣下個人專屬二維碼來提供閣下的電郵地址。或者,閣下也可以簽署回條並交回香港股份過戶登記分處。如果閣下所提供的電郵地址無效,直至香港股份過戶登記分處收到閣下有效的電郵地址前,閣下或(i)無法收到任何有關發佈公司通訊文件的通知;(ii)需要主動查看本公司網站和香港交易所披露易網站以留意公司通訊文件的發佈;及(iii)本公司未來將以印刷本形式發送可供採取行動的公司通訊文件

如 閣下欲收取本公司日後公司通訊文件之印刷本,請填妥回條,並使用隨附之郵寄標籤,寄回香港股份過戶登記分處(如在香港投寄,毋須貼上郵票;否則,請貼上適當的郵票)。你亦可把已填妥之回條的掃瞄副本電郵至 tul3933.ecom@computershare.com.hk。請注意,收取公司通訊文件印刷本之指示將直至本公司於翌年刊發下一份年度報告為止。

如對本函內容有任何疑問,請致電香港股份過戶登記分處 (852) 2862 8688,辦公時間為星期一至五(香港公眾假期除外)上午 9 時正至下午 6 時正或電郵至tul3933.ecom@computershare.com.hk 。

承董事會命 **聯邦制藥國際控股有限公司** 公司秘書 **梁永康**

2025年9月30日

附註: (1) 公司通訊文件包括但不限於:(a)董事會報告、年度財務報表連同核數師報告及如適用,財務簡要報告;(b)中期報告及如適用,中期摘要報告;(c)會議通告;(d)上市文件; (e) 頻前;及(f) 季仟代表表格。

(2) 可供採取行動的公司通訊文件指任何涉及要求本公司的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊文件。

REPLY FORM 回條						
	omputershare Hong Kong Investor S ne "Hong Kong Branch Share Re		致:	香港中央證券登記有限公司 (「香港股份過戶登記分處」)		
	M Floor, Hopewell Centre	gistrar)		香港灣仔皇后大道東 183 號		
18	3 Queen's Road East, Wanchai, H	ong Kong		合和中心 17M 樓		
(Please choos	se ONLY ONE of the options below)	(請 <u>從以下選項中只選擇其中一項</u>))			
Option 1	Option 1 Provide your email address for receipt of future Corporate Communications* of the Company via electronic 専屬二維碼					
	dissemination by scanning your personalized QR code					
選項 1	掃瞄 閣下專屬二維碼提供 閣下之電郵地址,以接收公司通過電子方式發佈的日後公司通訊。					
ENTER A TOTAL SECTION OF THE PROPERTY OF THE STATE OF THE						
	You are NOT required to return th	is Reply Form if you choose Option 1.				
	- 如選擇了選項 1 , 閣下 無須 交回	」 「本回條。				
Option 2 I/we hereby provide my/our email address in writing for receipt of future Corporate Communications of the following listed company						
	(the "Company") via electronic dissemination					
選項 2						
Name of securities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱:						
The United Laboratories International Holdings Limited						
聯邦制藥國際控股有限公司						
Email address 電郵地址: (Note 3 / 附註 3)						
Option 3	I/ b b	Comments Comments that is a size		141-441:	4- d- d d C	
Option 3 I/we hereby request for receipt of Corporate Communications in printed form and noted that this instruction is valid up to the time when the Company publishes its next annual report in the following year. (Note 5)						
選項 3 本人/吾等現要求收取公司通訊印刷版,並已知悉本指示將直至公司於翌年刊發下一份年度報告為止。						
(Please mark "✓" in the below box if applicable) (如適用,請在以下方格內劃上「✓」號)						
	Printed English version	Printed Chinese version		Both the printed English an	d Chinese versions	
	英文印刷本	中文印刷本	,,,	英文及中文印刷本	d Chinese versions	
6:						
Signature(s 簽名: ^{(附記}): (''''' '''' '''' '''' '''' ''''' ''''' ''''	Contact numb 聯絡電話號碼		Date: 日期:		
Notes 附註:						
 Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid. 請清楚填妥 閣下之所有資料。如屬聯名股東・助本回條須由所有聯名股東聯合簽署・方為有效。 Any Reply Form with no signature or otherwise incorrectly completed will be void. 						
任何回錄若未有簽署或在某他方面填寫不正確,則本回錄將會住籍。 3. If the Company does not receive a functional email address in your reply, you may be unable to receive notifications regarding the publication of Corporate Communications.						
如本公司沒有收到 關下的有效電郵地址, 關下或無法收到有關發佈公司通訊的通知。 4. If you provide more than one email address by QR code, email, Reply Form and/or other means, only the latest one email address provided will be registered.						
划 閣下通過二維碼、電郵、回條及J或其他方式提供多於一個的電郵地址,只有 閣下最後提供的電郵地址將會被用於登記。 5. If you mark "✓" in the box in Option 3, no email address will be registered and only Corporate Communications in printed form will be received.						
For the avoid						
為免存疑,在本回縣上的任何額外指示,本公司將不予處理。 * Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the						
annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明、公司通訊乃指本公司已發出或將子發出以供其任何證券的持有人参照或採取行動的任何文件,其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。 PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明						
(i) "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). 本學明中所持的「個人音彩,與声義決持傾等 486 章 (個人音彩,尽趣,答例)(「《永趣答例》,)中「個人音彩,如诗素身相同。						
(ii) Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications* and to liaise with you on other matters relating to your holdings in the Company, Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction						
and/or request as stated in this Reply Form. 周下於本回條所提供的個人資料將用於(包括但不限於)有關本公司以電子方式發佈公司適訊*及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。 閣下是自願向公司提供個人資料。若 閣下未能提供足夠資料,本公司可能無法處理 閣下在本回條上所述的指示及或要求。						
(iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Hong Kong Branch Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record oursoes.						
本公司可就任何所說明的用途或在法例規定的情況下,將 閻下的個人資料披露或轉換絡公司的解腦公司、香港股份總戶卷記分應、及域其他公司或團體,並將在適當期間保留該等個人資料作核賣及於總用途。 (iv) You have the right to request access to and/or correction of your Personal Data						
should be in writing, by mail to the Hong Kong Privacy Officer of the Hong Kong Branch Share Registrar at 17M Floor, Hopewell Céntre, 183 Queen's Road East, Wanchai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk. 图下有權根據 《私廳條例》的除文章閱及或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至香港股份過戶登記分處(地址為香港灣仔皇后大道東 183 號合和中心 17M 樓)向香港隱私主任提出,或發送電郵至 PrivacyOfficer@computershare.com.hk。						
向 下 月 惟 恨 的	E任提出,或發送電郵至 <u>PrivacyOfficer@compu</u>	.八東市「山口欧寺旦周汉/씨形以四八貝科則安? tershare.com.hk。	ハースの日田刀八野町三	c n / n l k l / n		

Х

MAILING LABEL 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港